Angioscopic observation three months after sirolimus-eluting stent implantation: Can we stop strong anti-platelet therapy after three months?

Japanese Journal of Interventional Cardiology

Volumn 21, Issue 5, 2006, Pages 409-416

  Kawakami, Hideo ^a,b   Matsuoka, Hiroshi ^a   Nakamura, Michitsugu ^a   Komatsu, Jiro ^a   Ito, Taketoshi ^a  

^a Ehime Prefectural Imabari Hospital   (Japan)

^b Ehime Prefectural Imabari Hospital   (Japan)

Author keywords

Coronary angioscopy; Neointimal formation; Sirolimus eluting stent

Indexed keywords

ACETYLSALICYLIC ACID; RAPAMYCIN; TICLOPIDINE;

ADULT; AGED; ANGIOCARDIOGRAPHY; ANGIOSCOPY; ARTICLE; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CATHETERIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HUMAN; INTIMA; MALE; THROMBOSIS;

EID: 33751232617     PISSN: 09148922     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Sousa JE, et al: Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103: 192-195, 2001.
2. Suzuki T, et al: Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model. Circulation 104: 1188-1193, 2001.
3. Morice MC, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 346: 1773-1780, 2002.
4. Virmani R, et al: Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent. Should we be cautious? Circulation 109: 701-705, 2004.
5. McFadden EP, et al: Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 364: 1519-1521, 2004.
6. Iakovou I, et al: Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 293: 2126-30, 2005.
7. Kuchulakant PK, et al: Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus-and paclitaxel-eluting stents. Circulation 113: 1108-1113, 2006.
8. Cutlip DE, et al: Stent thrombosis in the modern era: A pooled analysis of multicenter coronary stent clinical trials. Circulation 2001 103: 1967-1971, 2001.
9. Cheneau E, et al: Predictors of subacute stent thrombosis: Results of a systematic intravascular ultrasound study. Circulation 108: 43-47, 2003.
10. Weisz G, et al: Two-year outcomes after sirolimus-eluting stent implantation. Results from the sirolimus-eluting stent in de novo native coronary lesions (SIRIUS) trial. J Am Coll Cardiol 47: 1350-1355, 2006.
11. Mizuno K, et al: Angioscopic evaluation of coronary-artery thrombi in acute coronary syndromes. N Engl J Med 326: 287-291, 1992.
12. Y Ueda, et al: Intracoronary morphology of culprit lesions after reperfusion in acute myocardial infarction: serial angioscopic observations. J Am Coll Cardiol 27: 606-610, 1996.
13. Asakura M, et al: Remodeling of in-stent neointima, which became thinner and transparent over 3 years: Serial angiographic and angioscopic follow-up. Circulation 97: 2003-2006, 1998.
14. Ischemic Heart Disease Frontier 5: 5: 95-100, 2004.
15. Sakai S, et al: Morphologic changes in infarct-related plaque after coronary stent placement: A serial angioscopy study. J Am Coll Cardiol 42: 1558-1565, 2003.
16. Ueda Y, et al: The healing process of infarct-related plaques: Insights from 18 months of serial angioscopic follow-up. J Am Coll Cardiol 38: 1916-1922, 2001.
17. Moses JW, et al: Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349: 1315-1323, 2003.
18. Pharma Medica 23: 126-127, 2005.
19. Frederick GP, et al: Inflammation and restenosis in stent era. Molecular biology and post-angioplasty restenosis. Atheroscler Thromb Vasc Biol 22: 1769-1776, 2002.
20. Kip1 in vascular smooth muscle cell migration. Circulation 103: 2967-2972, 2001.
21. Marx SO, et al: Bench to Bedside: The development of rapamycin and its application to stent restenosis. Circulation 104: 852-855, 2001.
22. Poon M, et al: Rapamysin inhibits vascular smooth muscle cell migration. J Clin Invest 98: 2277-2283, 1996.
23. Steffel J, et al: Rapamycin, but not FK-506, increases endothelial tissue factor expression: Implications for drug-eluting stent design. Circulation 112: 2002-2011, 2005.
24. Walpoth BH, et al: Late coronary thrombosis secondary to a sirolimus-eluting stent response. Circulation 110: e309, 2004.
25. Uchida Y: Coronary angioscopy. Futura Publishing Company, Inc. Armonk, NY, 2001, pp 29-41.
26. Cip1. Mol Cell 11: 1491-1501, 2003.
27. Rossi ML, et al: Different quantitative apoptotic traits in coronary atherosclerotic plaques from patients with stable angina pectoris and acute coronary syndromes. Circulation 110: 1767-1773, 2004.